Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
Genes and genetic variations in our body contribute to the bodily functions and overall health. This also includes the possibility of having various diseases which are hereditary or developed in our body due to changes in the genetic codes. BRCA -1 & BRCA – 2 are two genes which are linked to He....
Yes it is. Women who consume even a few drinks a week possess an increased risk for breast cancer. Scientists still haven’t yet found out exactly why this happens. Alcohol may raise estrogen levels, an important factor in the development of breast cancer. One characteristic of a cancer cell is that ....
Vitamin B17 is not actually a vitamin. Vitamins are essential for human health. B17 is a poison also known as amygdalin as well as drugs. Amygdalin is broken down into cyanide, which is an incredibly toxic substance. There is zero reason to use it to treat cancer. There is no scientific evidence is ....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
كُتب بواسطة:Dr. Nitika Sharma - BDS
تمت مراجعته من قبل:Dr. Rakesh Kumar - MBBS, MS
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.